Novel aryl-bis-quinolines with antimalarial activity in-vivo

Journal of Pharmacy and Pharmacology

Volumn 50, Issue 5, 1998, Pages 483-492

  Ismail, F M D ^b   Dascombe, M J ^a   Carr, P ^b   Merette S A M ^b   Rouault, P ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PLASMODIUM BERGHEI;

EID: 0031776029     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1998.tb06189.x     Document Type: Article

References (61)

1. Albert, A. (1966) The connection between anti-malarial action and chemical structure in the acridine series. In: The Acridines, Their Preparation, Properties and Uses. 2nd edn, Edward Arnold, London, pp 469-492
2. Albert, A. (1985) Selective Toxicity: The Physiochemical Basis of Therapy. 7th edn, Chapman and Hall, London, pp 417-419
3. Bhattacharjee, A. K., Karl, J. M. (1996) Molecular electronic properties of a series of 4-quinolincarbinolamines define anti-malarial activity profile. J. Med. Chem. 39: 4622-4629
4. Biosym (1993) Insight II, Version 2.3.0, Biosym Technologies, San Diego, California 92121-2777
5. Bisby, R. H. (1990) Reactions of a free radical intermediate in the oxidation of amodiaquine. Biochem. Pharmacol. 39: 2051-2055
6. Blauer, G., Akkawi, M., Bauminger, E. R. (1993) Further evidence for the interaction of the anti-malarial drug amodiaquine with ferritoprotoporphyrin-IX. Biochem. Pharmacol. 46: 1573-1576
7. Chou, A. C., Chevli, R., Fitch, C. D. (1980) Ferriprotoporphyrin IX fulfils the criteria for identification as the chloroquine receptor of malaria parasites. Biochemistry 19: 1543-1549
8. Constantinidis, I., Saterlee, J. D. (1988) UV-visible and carbon NMR studies of chloroquine binding to urohemin (I) chloride and uroporphyrin (I) in aqueous solutions. J. Am. Chem. Soc. 110: 4391-4395
9. Cook, G. C. (1995) Adverse-effects of chemotherapeutic-agents used in tropical medicine. Drug Safety 13: 31-45
10. Cox, F. E. G. (1988) Major animal models in malaria research: rodent. In: Wernsdorfer, W. H., McGregor, I. (eds) Malaria-Principles and Practice of Malariology. Volume 2, Churchill Livingstone, Edinburgh, pp 1503-1543
11. De, D. Y., Krogstad, F. M., Cogswell, F. B., Krogstad, D. J. (1996) Aminoquinolines that circumvent resistance in Plasmodium falciparum in-vitro. Am. J. Trop. Med. Hyg. 55: 579-583
12. Douc-Rasy, S., Kayser, A., Riou, G. F. (1984) Inhibition of the reactions carried out by a type I topoisomerase and a catenating enzyme of Trypanosoma cruzi by DNA-intercalating drugs. Preferential inhibition of catenating reaction. EMBO J. 3: 11-16
13. Duchamp, D. J. (1990) Crystallography and molecular mechanics in designing drugs with unknown receptor structure. In: Bugg, C. E., Ealick, S. E. (eds) Crystallographic and Modern Methods in Molecular Design. Springer, Heidelberg, pp 161-174
14. Fadat, G., LeBras, J., Hengy, C., Louis, J. P., Gimou, M. M., Verdier, F. (1991) Efficacy of amodiaquine against chloroquine-resistant malaria in Cameroon. Lancet 338: 1092
15. Fletcher, D. A., McMeeking, R. F., Parkin, D. (1996) The United Kingdom Chemical Database Service. J. Chem. Inf. Comput. Sci. 36: 746-749
16. 1-diethyl-1,4-pentanediamine-an X-ray diffraction study of chloroquine phosphate hydrate. Acta Chem. Scand. 44: 741-745
17. Gamage, S. A., Tepsiri, M., Wilairat, P., Wojick, S. J., Figgit, D. P., Ralph, R. K., Denny, W. A. (1994) Synthesis and in-vitro activity of 9-anilino-3,6-diaminoacridines active against a multi-drug resistant strain of the malaria parasite Plasmodium falciparum. J. Med. Chem. 37: 1486-1494
18. Geary, T. G., Divo, A. D., Jensen, J. B., Zangwill, M., Ginsburg, H. (1990) Kinetic modelling of the response of Plasmodium falciparum to chloroquine and its experimental testing in-vitro. Implications for mechanism of action of and resistance to the drug. Biochem. Pharmacol. 40: 685-691
19. Ginsburg, H., Krugliak, M. (1992) Quinoline-containing anti-malarials - mode of action, drug resistance and its reversal: an update with unresolved puzzles. Biochem. Pharmacol. 43: 63-70
20. Harrison, A. C., Kitteringham, N. R., Clarke, J. B., Park, K. P. (1992) The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem. Pharmacol. 43: 1421-1430
21. Holtje, H.-D. (1996) In: Wermuth, C. G. (ed.) Pharmacophore Identification and Receptor Mapping in the Practice of Medicinal Chemistry. Academic Press. London, pp 437-457
22. Ismail, F. M. D., Dascombe, M. J., Carr, P., North, S. E. (1996) An exploration of the structure activity relationships of 4-aminoquinolines: novel anti-malarials with activity in-vivo. J. Pharm. Pharmacol. 48: 841-850
23. Jewell, H., Maggs, J. L., Harrison, A. C., O'Neill, P. M., Ruscoe, J. E., Park, B. K. (1995) Role of hepatic-metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica 25: 199-217
24. Krogstad, D. J., Gluzman, I. Y., Herwaldt, B. L., Schlesinger, P. H., Wellems, T. E. (1992) Energy-dependence of chloroquine accumulation and chloroquine efflux in Plasmodium falciparum. Biochem. Pharmacol. 43: 57-62
25. Kubinyi, H. (1997) QSAR and 3D QSAR in drug design Part 2: Applications and problems. Drug Discov. Today 2: 538-546
26. Looareesuwan, S., White, N. J., Chantavanich, P., Edwards, G., Nicholl, D. D., Bunchand, C., Warell, D. A. (1986) Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br. J. Clin. Pharmacol. 22: 31-36
27. MacroModel (1993) Version 4.0, Still, W. C., Columbia University, New York, NY 10027
28. Maggs, J. L., Tingle, M. D., Kitteringham, N. R., Park, B. K. (1988) Drug protein conjugates XIV. Mechanisms of formation of protein-arylating intermediates from amodiaquine a myletoxin and hepatoxin in man. Biochem. Pharmacol. 37: 303-311
29. Marie, C. (1993) Preparation of 4-Aryl-substituted Quinolines. H.N.D. Project, Division of Chemical Sciences, University of Hertfordshire, UK
30. Martiney, J. A., Cerami, A., Slater, A. F. G. (1995) Verapamil reversal of chloroquine resistance in the malaria parasite: Plasmodium falciparum is specific for resistant parasites and independent of the weak base effect. J. Biol. Chem. 270: 22393-22398
31. Meshnick, S. R. (1996) Is haemozoin a target for anti-malarial drugs? Ann. Trop. Med. Parasitol. 90: 367-372
32. Mohamadi, F., Richards, N. G. J., Guida, W. C., Liskamp, R., Caufield, C., Chang, G., Hendrickson, T., Still, W. C. (1990) MacroModel - an integrated software system for modelling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 11: 440-467
33. Muller, O., Vashensbroek, M. B., Jaffar, S., Drakeley, C., Okorie, C., Joof, D., Pinder, M., Greenwood, B. (1996) A randomized trial of chloroquine, amodiaquine and pyrimethamine-sulfadoxine in Gambian children with uncomplicated malaria. Trop. Med. Int. Health. 1: 124-132
34. Neftel, K. A., Woodtly, W., Schmid, M., Frick, P. G., Fehr, J. (1986) Amodiaquine induced agranulocytosis and liver damage. Br. Med. J. 292: 721-723
35. Olliaro, P., Nevil, C., LeBras, J., Ringwald, P., Mussano, P., Garner, P., Brasseur, P. (1996) Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348: 1196-1201
36. O'Neill, P. M., Willock, D. J., Hawley, S. R., Bray, P. G., Storr, R. C., Ward, S. A., Park, B. K. (1997) Synthesis, anti-malarial activity, and molecular modelling of tebuquine analogues. J. Med. Chem. 40: 437-448
37. Oxford Molecular (1993) Personal Interactive Modelling System (PIMMS) Version 1.42, South Parks Rd, Oxford OX1 3UB
38. Perrin, D. D., Armarego, W. L. (1988) Purification of Laboratory Chemicals. 3rd edn, Pergamon, Oxford
39. Pilch, D. S., Yu, C., Makhey, D., La Voie, E. J., Srinivasan, A. R., Olson, W. K., Sauers, R. R., Breslauer, K. J., Geacintov, N. E., Liu, L. F. (1997) Minor groove-directed and intercalative ligand-DNA interactions in the poisoning of human DNA topoisomerase I by protoberberine analogs. Biochemistry 36: 12542-12553
40. Pussard, E., Verdier, F. (1994) Anti-malarial 4-aminoquinolines: mode of action and pharmacokinetics. Fundam. Clin. Pharmacol. 8: 1-17
41. Ridley, R. G., Hofheinz, W., Matile, H., Jaquet, C., Dorn, A., Masciadri, R., Jolidon, S., Richter, W. F., Guenzi, A., Girometta, M. A., Urwyler, H., Huber, W., Thaithong, S., Peters, W. (1996) 4-Aminoquinoline analogs of chloroquine with shortened side-chains retain activity against chloro-quine-resistant Plasmodium falciparum. Antimicrob. Agents Chemother. 40: 1846-1854
42. 2-bis(7-chloroquinolin-4-yl)cyclohexane-1,2-diamine: comparison of two stereoisomers and detailed evaluation of the S,S enantiomer, Ro 47-7737. Antimicrob. Agents Chemother. 41: 677-686
43. Ruscoe, J. E., Jewel, H., Maggs, J. L., O'Neill, P. M., Storr, R. C., Ward, S. A., Park, B. K. (1995) The effect of chemical substitution on the metabolic activation, metabolic detoxification and pharmacological activity of amodiaquine in the mouse. J. Pharmacol. Exp. Ther. 273: 393-404
44. Sartorius, J., Schneider, H.-J. (1997) Intercalation mechanisms with dsDNA: binding modes and energy contributions with benzene, naphthalene, quinoline and indole derivatives including some anti-malarials. J. Chem. Soc. Perkin. Trans. 2 2319-2327
45. Singh, S., Puri, S. K., Singh, S. K., Srivastava, R., Gupta, R. C., Pandey, V. C. (1997) Characterization of simian malarial parasite (Plasmodium knowlesi)-induced putrescine transport in rhesus monkey erythrocytes - a novel putrescine conjugate arrests in vitro growth of simian malarial parasite (Plasmodium knowlesi) and cures multidrug resistant murine malaria (Plasmodium yoelii) infection in-vivo. J. Biol. Chem. 272: 13506-13511
46. Slater, A. F. G. (1993) Chloroquine-mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol. Ther. 57: 203-235
47. Slomianny, C., Clarebout, G., Gamain, B., Gratepanche, S., Dive, D. (1996) Enzymatic antioxidant defence system in malaria parasites. XIVth International Congress for Tropical Medicine and Malaria, Jpn Soc. Trop. Med., Nagasaki, B-26-1
48. Sorensen, M., Sehested, M., Jensen, P. B. (1997) pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the anti-malarial agent chloroquine. Biochem. Pharmacol. 54: 373-380
49. 2. Nucl. Acid Res. 25: 4072-4078
50. Stewart, J. J. P. (1990) Mopac - a semi-empirical molecular orbital program. J. Comput. Aided Mol. Des. 4: 1-45
51. Sullivan, D. J., Gluzman, I. Y., Russell, D. G., Goldberg, D. E. (1996) On the molecular mechanism of chloroquines anti-malarial action. Proc. Natl Acad. Sci. USA 93: 11865-11870
52. Thelu, J., Burnod, J., Bracchi, V., Ambroisethomas, P. (1994) Identification of differentially transcribed RNA and DNA helicase-related genes of Plasmodium falciparum. DNA Cell Biol. 1: 1109-1115
53. Tyman, J., Ghorbanian, S., Muir, M., Tychopoulos, V. (1989) Improved nucleophilic displacement in N-methylpyrrolidinone as a solvent. Synth. Commun. 19: 179-188
54. Vennerstrom, J. L., Ellis, W. Y., Ager Jr, A. L., Anderson, S. L., Gerena, L., Milhous, W. K. (1992) Bisquinolines 1. N, N-Bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria. J. Med. Chem. 35: 2129-2134
55. Ward, S. A., Bray, P. G., Hawley, S. R. (1997) Quinoline resistance mechanisms in Plasmodium falciparum: the debate goes on. Parasitology 114: S125-S136
56. Warhurst, D. C. (1987) Anti-malarial interaction with ferriprotoporphyrin IX and its interrelationship to activity of blood schinzontocides. Ann. Trop. Med. Parasitol. 81: 65-67
57. Watkins, W. M., Spencer, H. C., Kariuki, D. M., Sixsmith, D. G., Boriga, D. A., Kipingor, T., Koech, D. K. (1984) Effectiveness of amodiaquine as a treatment of chloroquine-resistant Plasmodium falciparum infections in Kenya. Lancet 1: 357-359
58. Werbel, L. M., Cook, D. P., Elslager, E. F., Hung, J. H., Johnson, J. L., Kesten, S. J., McNamara, D. J., Ortwine, D. F., Worth, D. F. (1986) Synthesis, anti-malarial activity and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolynyl)amino]-3-[(alkylamino)m-ethyl][1,1′-biphenyl]-2- ols and N-oxides. J. Med. Chem. 29: 924-939
59. Wermuth, C. G., Testa, B. (1996) Biotransformation Reactions in The Practice of Medicinal Chemistry. Wermuth, C. G. (ed.) Academic Press, London, pp 615-642
60. White, N. J., Looareesuwan, S., Edwards, G., Phillips, R. E., Karbwang, J., Nicholl, D., Bunch, C., Warell, D. A. (1987) Pharmacokinetics of intravenous amodiaquine. B. J. Clin. Pharmacol. 23: 127-135
61. Yennawar, H. P., Viswamitra, M. A. (1991) Steric and rotational constraints in the X-ray structure of the anti-malarial drug amodiaquine. Curr. Sci. 61: 39-43